Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

NCT02027779 ·Status: UNKNOWN ·Phase: PHASE3

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

NCT03061201 ·Status: COMPLETED ·Phase: PHASE2

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

NCT02541942 ·Status: COMPLETED ·Phase: PHASE2

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

NCT01712438 ·Status: COMPLETED ·Phase: PHASE3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719 ·Status: RECRUITING ·Phase: PHASE3

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

NCT00623480 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

NCT01181128 ·Status: COMPLETED ·Phase: PHASE3

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

NCT04845399 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

NCT01568580 ·Status: COMPLETED ·Phase: PHASE3

ATHN 7: Hemophilia Natural History Study

NCT03619863 ·Status: COMPLETED

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

NCT01811875 ·Status: TERMINATED ·Phase: PHASE4

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT01863758 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4

Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A

NCT00717626 ·Status: COMPLETED ·Phase: PHASE2

ADVATE Post Authorization Safety Surveillance

NCT00214734 ·Status: COMPLETED

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

NCT03754790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

NCT00168051 ·Status: WITHDRAWN ·Phase: PHASE4

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934 ·Status: ACTIVE_NOT_RECRUITING

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245 ·Status: COMPLETED ·Phase: PHASE3

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

NCT02954575 ·Status: COMPLETED ·Phase: PHASE3

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

NCT05707351 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

NCT03747653 ·Status: UNKNOWN

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301 ·Status: COMPLETED

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673 ·Status: TERMINATED ·Phase: PHASE4